As such, future studies will focus on exploring and testing novel gene promoters that specifically target NPC cells to achieve safer, more specific, robust and stable therapeutic effects for radionuclide therapy in NPC, and the use of more powerful therapeutic radionucleotides, such as 211At or 188Re, should be investigated in NPC cells expressing NIS. This evidence concerns the gene SLC5A5 and nasopharyngeal carcinoma.